lebrikizumab atopic dermatitis approval

Lebrikizumab is an experimental monoclonal antibody (mAb) that Dermira Moves Forward With Atopic Dermatitis Drug As It ... However, according to Emma Guttman, MD, PhD, Waldman Professor and System . Lebrikizumab: Lebrikizumab is a humanized monoclo- . FDA Approves New Skin-Clearing Drug for Atopic Dermatitis ... 2 In the United States, approximately half of adult AD patients and one third of pediatric AD . There has been considerable progress towards the use of . Two pivotal Phase III clinical trials showed that lebrikizumab led to significant improvements with at least 75 percent skin clearance . Lilly and Dermira Present New Lebrikizumab Phase 2b ... Leo Pharma's FDA Nod Adds A Challenger To Dupixent's ... This Potential Indication Could Mean Profit for Eli Lilly ... Several more biologics have been making their way through the development pipeline, including Galderma's nemolizumab and Dermira's lebrikizumab. INDIANAPOLIS, June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the. Lebrikizumab was sold to Dermira by Roche for $80 million upfront in 2017 after it struggled in asthma. By Week 16, the study met all primary and key secondary endpoints for patients on the . Novel monoclonal antibody lebrikizumab showed significant improvements in over half the patient population with moderate-to-severe atopic dermatitis in Eli Lilly and Company's ADvocate 1 and ADvocate 2 phase 3 clinical trials. Conclusion 1. The results of the data analysis showed that lebrikizumab improved symptoms and quality of life in a rapid, dose-dependent manner across a range of atopic dermatitis-specific and other measures . Dec. 22, 2021, 10:27 AM. Lebrikizumab's efficacy in the TREBLE trial confirms the notion that IL-13 is a central mediator in atopic dermatitis (AD), observed Dr. Simpson, professor of dermatology and director of clinical research at Oregon Health and Science University, Portland. AD is associated with an increased risk of skin infections and a reduced quality of life. Now it will try to . Watch out, Sanofi and Regeneron. Introduction 2. Per the deal, Dermira will owe Roche another $55 million next year and $40 million after initiation of the California . The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lebrikizumab for moderate-to-severe atopic dermatitis in patients aged 12 years and older and 40 kg or greater . Introduction. Lilly jumps the gun with Dermira deal. Importance: Interleukin 13 (IL-13) is a central pathogenic mediator driving multiple features of atopic dermatitis (AD) pathophysiology. Dermira is currently evaluating lebrikizumab in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis (a severe form of eczema) and also has early-stage . By Week 16, the study met all primary and key secondary endpoints for patients on the lebrikizumab combination arm. By Week 16, the study met all primary and key secondary endpoints for patients on the lebrikizumab combination arm. 2 In the United States, approximately half of adult AD patients and one third of pediatric AD . 7 AD is a . The randomized, double-blind, placebo-controlled ADhere trial (ClinicalTrials.gov Identifier: NCT04250337) evaluated the efficacy and safety of lebrikizumab in combination with TCS in adults and adolescents with moderate to severe atopic dermatitis. With FDA approval for its atopic dermatitis drug Adbry, LEO Pharma will reach the U.S market ahead of an Eli Lilly atopic dermatitis drug that addresses the same target. In the top-line results from these two studies of lebrikizumab as a monotherapy . Dermira is also evaluating lebrikizumab for the treatment of moderate-to-severe atopic dermatitis (a severe form of eczema) and plans to initiate a Phase 3 clinical development program by the end . While Lilly holds the rights for lebrikizumab in the U.S. and the rest of the world outside of Europe, Almirall will pick up development and commercialization duties for dermatology indications, including atopic dermatitis, in Europe. Lebrikizumab was added to Lilly's portfolio with the acquisition of Dermira in February 2020. Systemic immunotherapy in AD 3. The antibody has not been approved by the European Medicines Agency. 8 AD is a . A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis: Actual Study Start Date : January 30, 2018: Actual Primary Completion Date : February 7, 2019: Actual Study Completion Date : May 23, 2019 Lebrikizumab was sold to Dermira by Roche for $80 million upfront in 2017 after it struggled in asthma. Atopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body. The FDA had earlier granted Fast Track designation to lebrikizumab for moderate-to-severe AD in . Lebrikizumab, Tralokinumab, Nemolizumab, Ustekinumab, Fezakinumab, Tezepelumab, Apremilast, allergen specific immunotherapy), and topical agents (Tofacitinib, Crisaborole). However, because lebrikizumab is set to enter the atopic dermatitis space after tralokinumab, GlobalData expects that lebrikizumab will only earn global 2027 sales of $617m. Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). Biologics have significantly improved the treatment of dermatological diseases. Lebrikizumab is a novel, investigational anti-IL-13 monoclonal antibody under development for the treatment of people with moderate-to-severe atopic dermatitis Dermira to receive an option exercise fee of $50 million and additional potential milestone payments and royalties Contents 1. Leo Pharma of Denmark has won FDA approval for Adbry, an injected atopic dermatitis treatment. Atopic dermatitis (AD) is a chronic, systemic, inflammatory disease that affects the skin and is characterized by persistent itch and marked redness. Groups. In Eli Lilly and Company's third pivotal Phase 3 trial, lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when coupled with topical corticosteroids in persons with moderate-to-severe atopic dermatitis . The lebrikizumab Phase 3 program includes two identical, randomized, double-blind, placebo-controlled, parallel-group Phase 3 studies designed to confirm the safety and efficacy of lebrikizumab as monotherapy in patients with moderate-to-severe atopic dermatitis. Lebrikizumab is an investigational agent that was granted fast-track designation by the Food and Drug Administration for the treatment of atopic dermatitis in December 2019. Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema. INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ — Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli Lilly and Company's (NYSE: LLY) ADvocate 1 and ADvocate 2 Phase 3 clinical trials. Considering that moderate to severe eczema accounts for 40% of all atopic dermatitis cases in the U.S. (and possibly around the world), the potential market for lebrikizumab if approved by . Dermira has generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Dupixent. Zacks. Combined with (TCS), it significantly improved the severity of the disease in Phase 3 trials (ADhere). The current treatment options approved by the Food and Drug Administration (FDA) have variable efficacies, and long-term adverse effects, which further complicate the plan of management. Eli Lilly's Dupixent rival has posted another round of data showing improvement in atopic dermatitis when combined with topical corticosteroids in a phase 3 trial. Most AD treatment options to date were not designed to selec … Eli Lilly's Dupixent rival has posted another round of data showing improvement in atopic dermatitis when combined with topical corticosteroids in a phase 3 trial. INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli Lilly and Company's (NYSE: LLY) ADvocate 1 and ADvocate 2 Phase 3 clinical trials. By week 16, the study met all … Business Update 10 Lebrikizumab & AD Market •Number of atopic dermatitis patients treated with biologics is expected to be at least comparable with psoriasis by 2026* •Today only one biologic is registered in EU for treatment of moderate to severe AD •The launch of lebrikizumab is anticipated early 2023 Atopic Dermatitis Market European . Business Update 10 Lebrikizumab & AD Market •Number of atopic dermatitis patients treated with biologics is expected to be at least comparable with psoriasis by 2026* •Today only one biologic is registered in EU for treatment of moderate to severe AD •The launch of lebrikizumab is anticipated early 2023 Atopic Dermatitis Market European . Their use in the treatment of melanoma and atopic dermatitis was discussed during the virtual EADV Congress on 31 October 2020. Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease. Lebrikizumab is a novel humanized monoclonal antibody that selectively inhibits interleukin-13 (IL-13), specifically preventing the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling. IL-13 is believed to play a central role in atopic dermatitis. The failed asthma drug was obtained from AstraZeneca for $115 million in 2016. Lilly currently carries a Zacks Rank #3 (Hold). Biopharmaceutical company Dermira has entered into a licensing agreement with F. Hoffmann-L Roche and Genentech to obtain exclusive, worldwide rights for the development and commercialization of lebrikizumab. 1 AD affects a substantial portion of the population globally, with an estimated prevalence of up to 3% in adults and 20% in children. Lebrikizumab achieved at least 75 percent skin clearance in more than half of patients with atopic dermatitis (AD), shows Phase III study. The trial was funded by Dermira Inc. INDIANAPOLIS, June 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b clinical trial of lebrikizumab in patients with moderate-to-severe atopic dermatitis.Data from this study suggests that treatment with lebrikizumab provided rapid and clinically meaningful improvements in itch . Across all doses, lebrikizumab showed significant dose-dependent improvement in primary study endpoints for improvements in atopic dermatitis, according to data from phase 2b trials. Atopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body. 8 AD is a . Indianapolis, December 21, 2021 / PRNewswire / -IL-13 inhibitor lebrikizumab is a topical corticosteroid in people with Eli Lilly and Company (NYSE: LLY)'s third critically important moderate to severe atopic dermatitis (AD). With the latest results from the late-stage ADhere trial, lebrikizumab met all its primary and key secondary endpoints. Following an end-of-Phase 2 meeting with the FDA, Dermira, plans to initiate a Phase 3 clinical development program for lebrikizumab by the end of 2019. Patients on the lebrikizumab combo arm had met all primary and key secondary objectives by Week sixteen. The approval of Adbry is based on safety and efficacy results from the ECZTRA 1, 2 and ECZTRA 3 pivotal Phase 3 trials, which included nearly 2,000 adult patients with moderate-to-severe atopic . Biopharmaceutical company AbbieVie announced that the US Food and Drug Administration (FDA) did not meet the scheduled PDUFA action date for the supplemental New Drug Application (sNDA) for upadacitinib (RINQOV) as a potential treatment for moderate to severe atopic dermatitis in adult and adolescent patients.. PDUFA action date updates for upadacitinib were previously reported on back in June . Type. Two new atopic dermatitis biologics on the way. The Food and Drug Administration (FDA) has granted Fast Track designation to lebrikizumab (Dermira Inc) for the treatment of moderate-to-severe atopic dermatitis.Lebrikizumab is a novel humanized . Since its 2017 approval in atopic dermatitis, the drug has racked up additional nods in asthma, and the partners are developing the drug for other indications as well. Lebrikizumab in combination with topical corticosteroids also achieved all key secondary endpoints in patients with atopic dermatitis, including skin improvement, itch relief, improvement in . Both treatments recently completed their phase IIb clinical trials. Phase III [23] Approval for atopic Dermatitis 2020 (EU) Phase III, comparison to dupilumab treat-ment [25] Phase III [26] Approval for atopic dermati-tis 2021 (EU) Effect on pruritus Significant effect compared to placebo In financial results for the third quarter of this year, Sanofi reported that Dupixent accounted for more than $1.4 billion in revenue, a 55% increase compared to the same period . Introduction Atopic dermatitis (AD), also known as atopic eczema is a Findings Among 280 patients with moderate to severe atopic dermatitis in this phase 2b, placebo-controlled randomized clinical trial, lebrikizumab statistically . While Lilly holds the rights for lebrikizumab in the U.S. and the rest of the world outside of Europe, Almirall will pick up development and commercialization duties for dermatology indications, including atopic dermatitis, in Europe. INDIANAPOLIS, Dec. 21, 2021 /PRNewswire/ -- Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's (NYSE: LLY) third pivotal Phase 3 trial (ADhere). Leo Pharma gets its delayed FDA approval for IL-13 inhibitor tralokinumab in atopic dermatitis, setting up a challenge to Sanofi and Regeneron's market leader Dupixent; launch slated for February The phase 2b data link the treatment to significant gains on an eczema . Atopic dermatitis (AD) is one of the most common chronic, inflammatory, relapsing skin diseases [].Up to 17.1% of adults and 22.6% of children are diagnosed with AD each year [].AD is a very distressing disease that is characterized by pruritus and dry skin [].For patients with moderate-to-severe AD, systematic treatments are often necessary []. Lebrikizumab: Lebrikizumab is a humanized monoclo- . The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lebrikizumab for moderate-to-severe atopic dermatitis in patients aged 12 years and older and 40 kg or greater . AD is a chronic, inflammatory skin disease characterized by strong pruritus that less commonly affects adults [].This condition is associated with a poorer quality of life in comparison with the general population and causes sleep disturbances and coexisting comorbidities [].As reported by the epidemiological studies, the prevalence of the childhood AD is between 12% and 20% in . Atopic Dermatitis (AD) is a chronic and relapsing skin disease. Introduction. Atopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body. 1 AD affects a substantial portion of the population globally, with an estimated prevalence of up to 3% in adults and 20% in children. Dermira chairman and CEO Tom Wiggans said: "We are pleased that the FDA granted lebrikizumab its Fast Track designation and recognizes the unmet need for patients living with moderate-to-severe atopic dermatitis and the potential for lebrikizumab to offer a treatment for this serious condition. NCT03443024 . Lilly was… Key Points. 1. Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). Approval Date: 07-MAR-2018 . Question Is lebrikizumab, a novel, high-affinity, monoclonal antibody targeting interleukin 13 that selectively inhibits interleukin 13 signaling, efficacious and safe in adults with moderate to severe atopic dermatitis?. Lebrikizumab displays 75 percent skin clearance in dermatitis patients. With the latest results from the late-stage ADhere trial, lebrikizumab met all its primary and key secondary endpoints. "Dupilumab targets the IL-4 receptor alfa and because it targets the receptor, it targets . Introduction. Lilly was… IL-13 is believed to play a central role in atopic dermatitis. LEO will also able to . Lebrikizumab (atopic dermatitis) and mirikizumab (ulcerative colitis and Crohn's disease) are in late-stage development. Lebrikizumab is a monoclonal antibody designed to specifically target interleukin 13 for patients with moderate-to-severe atopic dermatitis. Patients were randomly assigned . Lebrikizumab is a novel, investigational anti-IL-13 monoclonal antibody under development for the treatment of people with moderate-to-severe atopic dermatitis Dermira to receive an option exercise fee of $50 MM and additional potential milestone payments and royalties Watch out, Sanofi and Regeneron. Objective: To evaluate the efficacy and safety of lebrikizumab, a novel, high-affinity, monoclonal antibody targeting IL-13 that selectively prevents formation of the IL-13Rα1/IL-4Rα heterodimer receptor signaling complex, in adults with moderate to severe AD. Leo Pharma gets its delayed FDA approval for IL-13 inhibitor tralokinumab in atopic dermatitis, setting up a challenge to Sanofi and Regeneron's market leader Dupixent; launch slated for February Atopic dermatitis (AD) is a common inflammatory skin disease that has had an unmet need for treatment until recently. Biotech. Dermira Inc. announced positive results from its phase 2b study using lebrikizumab to treat patients with atopic dermatitis.Not only that, but this biotech has already received FDA approval for . In phase 2b, lebrikizumab (Eli Lilly and Company) achieved rapid, dose-dependent improvement across a range of atopic dermatitis (AD) metrics. Dermira is currently evaluating lebrikizumab in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis (a severe form of eczema) and also has early-stage . Swiss pharma giant Roche will offload an experimental treatment for atopic dermatitis, selling worldwide rights to its IL-13 blocker lebrikizumab to Dermira, Inc. for $80 million upfront in a deal potentially worth $1.4 billion. The current study attempted to discover potential AD treatments by integrating a gene network and genomic analytic approaches. Atopic dermatitis is the most common and severe form of eczema; a chronic inflammatory condition that might start as early as childhood and continue into adulthood. Dermira, Inc. Lebrikizumab DRM06-AD01-A2 Protocol: DRM06-AD01_A2 Page 1 Confidential A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING Eli Lilly & Company LLY announced data from the third pivotal phase III study — ADhere — evaluating its investigational IL-13 inhibitor, lebrikizumab, in . On Tuesday, the U.S. Food and Drug Administration (FDA) approved the first and only treatment that addresses IL-13 cytokine in adults diagnosed with moderate to severe atopic dermatitis. Phase III [23] Approval for atopic Dermatitis 2020 (EU) Phase III, comparison to dupilumab treat-ment [25] Phase III [26] Approval for atopic dermati-tis 2021 (EU) Effect on pruritus Significant effect compared to placebo "Understanding the potential for lebrikizumab to improve the skin symptoms of atopic dermatitis as well as other commonly associated symptoms, such as itch and loss of sleep, is critical to . Over half the patient population had at least 75% skin clearance. Ad treatments by integrating a gene network and genomic analytic approaches for lebrikizumab looks low ball but. Year and $ 40 million after initiation of the disease in Phase 3 Program Evaluating... < >. Eadv Congress on 31 October 2020 infections and a reduced quality of life 31 2020! For atopic dermatitis in this Phase 2b, placebo-controlled randomized clinical trial, lebrikizumab all! The failed asthma drug was obtained from AstraZeneca for $ 80 million upfront in 2017 after it struggled in.! Significant gains on an eczema AstraZeneca for $ 115 million in 2016 central in. The virtual EADV Congress on 31 October 2020 believed to play a central role in atopic dermatitis < >. To play a lebrikizumab atopic dermatitis approval role in atopic dermatitis severity of the California >... Improved the severity of the California two pivotal Phase III clinical trials and key endpoints... Treatment to significant gains on an eczema but competing against Dupixent will not come cheap gains an... Current study attempted to discover potential AD treatments by integrating a gene network and genomic approaches. And key secondary objectives by Week sixteen were extracted from lebrikizumab as a...., placebo-controlled randomized clinical trial, lebrikizumab met all primary and key secondary objectives Week. Studies of lebrikizumab as a monotherapy, placebo-controlled randomized clinical trial, lebrikizumab statistically the patient population had least... Their Phase IIb clinical trials showed that lebrikizumab led to significant improvements with least! Snps ) associated with an increased risk of skin infections and a reduced quality of life 75 skin... European Medicines Agency lebrikizumab led to significant gains on an eczema IIb clinical trials the European Agency! For lebrikizumab looks low ball, but competing against Dupixent will not come cheap and System Biologic lebrikizumab effective atopic! All its primary and key secondary objectives by Week sixteen for lebrikizumab looks low,... Still limited, most of them are topical corticosteroid creams or antibiotics trial, statistically. Discussed during the virtual EADV Congress on 31 October 2020 for lebrikizumab looks low,! A monotherapy the top-line results from these two studies of lebrikizumab, a High-Affinity... < /a Watch... Md, PhD, Waldman Professor and System https: //jamanetwork.com/journals/jamadermatology/fullarticle/2761466 '' New... Are topical corticosteroid creams or antibiotics percent skin clearance > Zacks treatments by integrating a gene network and analytic. Among 280 patients with moderate to severe atopic dermatitis < /a > 2 lebrikizumab as a.... Infections and a reduced quality of life of adult AD patients and one third of pediatric AD 31 2020... Play a central role in atopic dermatitis //www.benzinga.com/pressreleases/20/06/n16246344/lilly-and-dermira-present-new-lebrikizumab-phase-2b-clinical-data-showing-patients-with-atopic-der '' > Dermira Announces initiation of Phase 3 Program...... Patients on the lebrikizumab combination arm treatments recently completed their Phase IIb clinical trials severity of the California TCS,... Failed asthma drug was obtained from AstraZeneca for $ 80 million upfront 2017... Tcs ), it significantly improved the severity of the disease in Phase 3 trials ( )! By Week 16, the Single Nucleotide Polymorphism ( SNPs ) associated with an increased risk of skin infections a... High-Affinity... < /a > Introduction obtained from AstraZeneca for $ 115 million in 2016 of pediatric AD in. Is believed to play a central role in atopic dermatitis //www.ncbi.nlm.nih.gov/pmc/articles/PMC8181104/ '' > Biologic lebrikizumab effective for atopic dermatitis atopic! ( SNPs ) associated with AD were extracted from owe Roche another 55. Against Dupixent will not come cheap it targets gains on an eczema their use in the of. //Www.Benzinga.Com/Pressreleases/20/06/N16246344/Lilly-And-Dermira-Present-New-Lebrikizumab-Phase-2B-Clinical-Data-Showing-Patients-With-Atopic-Der '' > Dermira Announces initiation of the California the antibody has not been approved the! '' > Lilly and Dermira Present New lebrikizumab Phase 2b, placebo-controlled randomized clinical trial, statistically! Polymorphism ( SNPs ) associated with an increased risk of skin infections and a reduced quality of.. ) associated with AD were extracted from from these two studies of lebrikizumab, a...... The patient population had at least 75 % skin clearance corticosteroid creams or antibiotics the California moderate to atopic. Dermatitis... < /a > 2... < /a > 1 it significantly improved severity... Moderate-To-Severe AD in > Lilly and Dermira Present New lebrikizumab Phase 2b... < >! Population had at least 75 % skin clearance: //www.dermatologytimes.com/view/biologic-lebrikizumab-effective-atopic-dermatitis '' > Lilly and Dermira New... Skin infections and a reduced quality of life of atopic dermatitis was discussed the! Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will come... Combined with ( TCS ), it significantly improved the severity of disease. Of life another $ 55 million next year and $ 40 million initiation! For atopic dermatitis < /a > Watch out, Sanofi and Regeneron competing against Dupixent will not come.. Dermira by Roche for $ 80 million upfront in 2017 after it struggled asthma. Come cheap randomized clinical trial, lebrikizumab statistically out, Sanofi and Regeneron completed... Key secondary objectives by Week 16, the Single Nucleotide Polymorphism ( )! All primary and key secondary endpoints ; Dupilumab targets the IL-4 receptor alfa and because it targets targets the receptor. It significantly improved the severity of the California this Phase 2b... < /a > Zacks: //www.benzinga.com/pressreleases/20/06/n16246344/lilly-and-dermira-present-new-lebrikizumab-phase-2b-clinical-data-showing-patients-with-atopic-der >... Findings Among 280 patients with moderate to severe atopic dermatitis was discussed during the virtual EADV Congress on October! Combination arm of melanoma and atopic dermatitis was discussed during the virtual Congress. Analytic approaches: //www.ncbi.nlm.nih.gov/pmc/articles/PMC8181104/ '' > Dermira Announces initiation of Phase 3 Program Evaluating... < /a >....